Drug Profile
Research programme: erectile dysfunction therapies - Sagene Pharmaceuticals
Alternative Names: Selegiline/phosphodiesterase-5 inhibitor; SPI-1972Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Sagene Pharmaceuticals
- Class Erectile dysfunction therapies; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Erectile dysfunction in USA (PO) (Sagene Pharmaceuticals pipeline; December 2022)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO)
- 28 Feb 2018 Preclinical development for erectile dysfunction therapies is ongoing in USA (Sagene Pharmaceuticals pipeline, February 2018)